NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) today announced that the first of its disease-directed clinical trials of the anti-vascular endothelial growth factor receptor-2 (VEGFR-2) monoclonal antibody IMC-1121B has opened for patient enrollment.
